Sulfo-NHS-SS-Biotin for Surface Proteomics

2026-09-04

Sulfo-NHS-SS-Biotin combines water-soluble amine reactivity with a cleavable disulfide linker, enabling selective live-cell surface labeling and controlled affinity release. Its workflow flexibility supports protein purification, interaction mapping, and assays inspired by emerging cell-surface glycoRNA–RBP biology.

Gemcitabine as a Mechanistic Probe in Cancer Research

2026-09-03

A translational framework for using Gemcitabine to connect DNA replication stress, checkpoint signaling, apoptosis, and cancer stem cell biology. The article integrates the TAK1–YAP gastric cancer stem cell study with practical assay design and strategic guidance for preclinical researchers.

Niclosamide Workflows for STAT3 Cancer Research

2026-09-03

Build reproducible Niclosamide experiments around STAT3 Tyr-705 phosphorylation, apoptosis, and cell-cycle readouts rather than relying on viability alone. A genotype-aware strategy inspired by ATRX-deficient glioma research helps extend this small-molecule workflow into better controlled cancer models without overstating the evidence.

Mianserin HCl: From 5-HT2 Biology to Translation

2026-09-02

A translational perspective on Mianserin HCl as a 5-HT2 receptor antagonist, integrating receptor pharmacology, historical clinical evidence, assay design, cyclodextrin chemistry, and exploratory antipathogenic research.

ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

2026-09-02

The reference study shows that tunicamycin-induced endoplasmic reticulum stress damages the small-intestinal mucosa by reducing intestinal stem-cell abundance and differentiation capacity while increasing crypt apoptosis. Its central contribution is the mechanistic association of these effects with GRP78/ATF6/CHOP activation and suppression of p44/42 MAPK signaling, providing a framework for separating stem-cell loss from broader epithelial injury.

SB-505124 Hydrochloride: Assay Workflows

2026-09-01

Build more interpretable TGF-β pathway assays with SB-505124 hydrochloride, from Smad2/3 phosphorylation checks to fibroblast activation and tissue-remodeling models. The workflow also shows how to connect pathway inhibition with cancer-cell mechanics without confusing ALK signaling effects with direct BK-channel modulation.

Ceftolozane/Tazobactam: Mechanism, PK, and Resistance

2026-09-01

The reference review presents ceftolozane/tazobactam as an integrated strategy against resistant Gram-negative pathogens, combining potent cephalosporin activity with β-lactamase inhibition. Its analysis connects PBP binding, susceptibility patterns, pharmacokinetics, pharmacodynamics, clinical dosing, and safety, providing a useful framework for designing antibacterial studies.

Torin2: A Selective mTOR Inhibitor Guide

2026-08-31

Torin2 is a potent, selective mTOR inhibitor for mechanistic cancer research. Its reported activity in medullary thyroid carcinoma models and animal tumor studies supports pathway-focused experiments, while recent RNA Pol II research clarifies why apoptosis should not automatically be attributed to transcriptional loss.

Gramine Suppresses TNBC via CUL3–MTDH Ferroptosis

2026-08-31

A 2026 study identifies gramine as a selective inhibitor of triple-negative breast cancer and links its activity to a previously underdefined CUL3–MTDH regulatory axis. By combining target-engagement assays, genetic perturbation, ferroptosis rescue, and mouse models, the work supports a mechanistic route for inducing ferroptotic cancer-cell death.

AZD1480: Reliable JAK2/STAT3 Assays

2026-08-30

A practical, scenario-based guide to using AZD1480 (SKU A4137) in viability, proliferation, cytotoxicity, and pathway-validation workflows. It covers solvent control, assay interpretation, combination studies, and vendor-selection criteria for reproducible JAK2/STAT3 research.

Hypoxia and Immunometabolism in the Tumor Microenvironment

2026-08-29

This 2025 Cancer Letters review integrates tumor hypoxia, metabolic reprogramming, nutrient competition, and immune dysfunction into a reinforcing model of immunosuppressive tumor microenvironment development. Its practical value lies in showing why oxygen, nutrient, immune-cell, and redox measurements should be interpreted as connected variables rather than isolated endpoints.

Dimethoxy-Tolazoline Derivatives and α2 Receptors

2026-08-28

The reference study showed that moving two methoxy groups around the Tolazoline aromatic ring profoundly changed α1- and α2-adrenoreceptor efficacy, selectivity, and antagonist activity. Its combination of isolated-organ pharmacology and rat-cortex radioligand binding provides a useful structure–activity framework for interpreting imidazoline receptor probes without assuming that closely related analogues share the same mechanism.

Central Control of Opioid Mechanical Hypersensitivity

2026-08-28

Yin et al. identify a lateral parabrachial–hypothalamic–spinal opioid pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The findings distinguish mechanical pain control from better-established thermal mechanisms and show how local MOR activation with DAMGO can expose a circuit-level vulnerability relevant to opioid receptor signaling research.

Neticonazole Hydrochloride: From Fungi to Tumors

2026-08-27

Neticonazole Hydrochloride illustrates how a clinically used topical imidazole antifungal can become a hypothesis-generating tool for colorectal cancer research. This thought-leadership analysis connects fungal cell membrane synthesis inhibition with exosome biology, Bcl-2/Bax-regulated apoptosis, and colon-localized delivery while clearly separating established use from early translational opportunity.

Plk1 Control of p31comet in Checkpoint Disassembly

2026-08-27